Capsaicin causes inactivation and degradation of the androgen receptor by inducing the restoration of miR-449a in prostate cancer

Oncology Reports

Volumn 34, Issue 2, 2015, Pages 1027-1034

  Zheng, Long ^a   Chen, Jiaqi ^a   Ma, Zhenkun ^a   Liu, Wei ^a   Yang, Fei ^a   Yang, Zhao ^a   Wang, Ke ^a   Wang, Xinyang ^a   He, Dalin ^a   Li, Lei ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Androgen receptor; Capsaicin; Growth inhibition; miR 449a; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CAPSAICIN; CYCLIN D1; MESSENGER RNA; MICRORNA; MICRORNA 449A; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; MIRN449 MICRORNA, HUMAN;

ANDROGEN RECEPTOR GENE; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE INACTIVATION; HUMAN; HUMAN CELL; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATIC NEOPLASMS;

CAPSAICIN; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84931336766     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4055     Document Type: Article

References (29)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium: Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 375: 1437-1446, 2010.
3. Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170, 2002.
4. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004.
5. Chen Y, Clegg NJ and Scher HI: Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol 10: 981-991, 2009.
6. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68: 4447-4454, 2008.
7. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K and Sawyers CL: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765, 2010.
8. Díaz-Laviada I and Rodriguez-Henche N: The potential antitumor effects of capsaicin. Progr Drug Res 68: 181-208, 2014.
9. Sánchez AM, Malagarie-Cazenave S, Olea N, Vara D, Chiloeches A and Díaz-Laviada I: Apoptosis induced by capsaicin in prostate PC-3 cells involves ceramide accumulation, neutral sphingomyelinase, and JNK activation. Apoptosis 12: 2013-2024, 2007.
10. Jansson MD and Lund AH: MicroRNA and cancer. Mol Oncol 6: 590-610, 2012.
11. Noonan EJ, Place RF, Basak S, Pookot D and Li LC: miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 1: 349-358, 2010.
12. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C and Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28: 1714-1724, 2009.
13. Kusuda R, Cadetti F, Ravanelli MI, Sousa TA, Zanon S, De Lucca FL and Lucas G: Differential expression of microRNAs in mouse pain models. Mol Pain 7: 17, 2011.
14. Gill R, Kuriakose R, Gertz ZM, Salloum FN, Xi L and Kukreja RC: Remote ischemic preconditioning for myocardial protection: Update on mechanisms and clinical relevance. Mol Cell Biochem 402: 41-49, 2015.
15. Jankovic B, Loblaw DA and Nam R: Capsaicin may slow PSA doubling time: Case report and literature review. Can Urol Assoc J 4: E9-E11, 2010.
16. Chakraborty S, Mazumdar M, Mukherjee S, Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A and Das T: Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells. FEBS Lett 588: 549-559, 2014.
17. Kaymaz BT, Cetintas Kaymaz VB, Aktan C and Kosova B: MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin. Tumour Biol 35: 8733-8742, 2014.
18. Sánchez AM, Martínez-Botas J, Malagarie-Cazenave S, Olea N, Vara D, Lasunción MA and Díaz-Laviada I: Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: A microarray study. Biochem Biophys Res Commun 372: 785-791, 2008.
19. Mori A, Lehmann S, O'Kelly J, Kumagai T, Desmond JC, Pervan M, McBride WH, Kizaki M and Koeffler HP: Capsaicin, a component of red peppers, inhibits the growth of androgenindependent, p53 mutant prostate cancer cells. Cancer Res 66: 3222-3229, 2006.
20. Venier NA, Colquhoun AJ, Sasaki H, Kiss A, Sugar L, Adomat H, Fleshner NE, Klotz LH and Venkateswaran V: Capsaicin: A novel radio-sensitizing agent for prostate cancer. Prostate 75: 113-125, 2015.
21. Park M-T and Lee S-J: Cell cycle and cancer. J Biochem Mol Biol 36: 60-65, 2003.
22. Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, et al: ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14: 74-83, 2012.
23. Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S and Chang C: Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 288: 19359-19369, 2013.
24. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S and Chang C: Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 4: e764, 2013.
25. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, et al: 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993, 2002.
26. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP and Gao AC: MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 287: 1527-1537, 2012.
27. Epis MR, Giles KM, Barker A, Kendrick TS and Leedman PJ: miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 284: 24696-24704, 2009.
28. Sikand K, Slaibi JE, Singh R, Slane SD and Shukla GC: miR 488∗inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer 129: 810-819, 2011.
29. Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, et al: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71: 1956-1967, 2011.